University Of Tasmania

File(s) not publicly available

The serine proteinase inhibitor (Serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming

journal contribution
posted on 2023-05-16, 11:12 authored by Antalis, TM, Linn, ML, Donnan, K, Mateo, L, Gardner, J, Joanne DickinsonJoanne Dickinson, Buttigieg, K, Suhrbier, A
The serine proteinase inhibitor (serpin) plasminogen activator inhibitor type 2 (PAI-2) is well characterized as an inhibitor of extracellular urokinase-type plasminogen activator. Here we show that intracellular, but not extracellular, PAI-2 protected cells from the rapid cytopathic effects of alphavirus infection. This protection did not appear to be related to an effect on apoptosis but was associated with a PAI-2-mediated induction of constitutive low-level interferon (IFN)-α/β production and IFN-stimulated gene factor 3 (ISGF3) activation, which primed the cells for rapid induction of antiviral genes. This primed phenotype was associated with a rapid development of resistance to infection by the PAI-2 transfected cells and the establishment of a persistent productive infection. PAI-2 was also induced in macrophages in response to viral RNA suggesting that PAI-2 is a virus response gene. These observations, together with the recently demonstrated PAI-2-mediated inhibition of tumor necrosis factor-α induced apoptosis, (a) illustrate that PAI-2 has an additional and distinct function as an intracellular regulator of signal transduction pathway(s) and (b) demonstrate a novel activity for a eukaryotic serpin.


Publication title

Journal of Experimental Medicine










Menzies Institute for Medical Research


The Rockefeller University Press

Place of publication

New York USA

Repository Status

  • Restricted

Socio-economic Objectives

Other health not elsewhere classified

Usage metrics

    University Of Tasmania